News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ceragenix Pharmaceuticals, Inc. (CGXP.OB) And Nobel Biocare Enter into Option to License Agreement for Antimicrobial Technology


7/9/2009 9:03:01 AM

DENVER--(BUSINESS WIRE)--Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP), a medical device company focused on infectious disease and dermatology, today announced that it has entered into an exclusive evaluation and option to license agreement with Nobel Biocare , the world leader in innovative restorative and esthetic dental solutions. Under terms of the Agreement, Nobel Biocare will have an exclusive period to evaluate, negotiate commercialization terms and license the Company’s Cerashield™ antimicrobial technology for certain oral and cranial maxillofacial applications for a period of up to eleven months. This is the third such agreement entered into by Ceragenix for a medical device application of its CeraShield™ antimicrobial technology.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES